Physician profile
Michael C Trahos
NPI 1851570899
$4,254.73
in general payments reported to CMS, 2019-2025
33 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $894 · 2021: $853 · 2022: $599 · 2023: $459 · 2024: $360 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $393.02 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $314.17 | 2021-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $286.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.13 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $226.61 | 2019-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $218.64 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Allergan, INC. | $180.14 | 2019-2020 | |
| Lilly USA, LLC | $163.39 | 2019-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $147.89 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $135.11 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $113.52 | 2021-2023 | |
| Novo Nordisk INC | $112.49 | 2019-2025 | Ozempic |
| Collegium Pharmaceutical, INC. | $109.81 | 2020-2025 | Belbuca |
| Adlon Therapeutics L.P. | $109.26 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $106.85 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $104.54 | 2022-2024 | Rexulti |
| Medicure Pharma INC. | $90.71 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $89.36 | 2019-2021 | |
| Horizon Therapeutics Plc | $81.92 | 2019-2022 | |
| Eisai INC. | $66.10 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $63.41 | 2019 | |
| Mylan Specialty L.P. | $54.38 | 2020 | |
| Scilex Pharmaceuticals INC. | $53.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.14 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $41.60 | 2021 | |
| Biodelivery Sciences International, INC. | $40.56 | 2019-2021 | |
| Exact Sciences Corporation | $35.07 | 2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $19.00 | 2022 | |
| Redhill Biopharma INC. | $18.06 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.46 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Trahos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.